Quick Answer
CAPRICOR THERAPEUTICS, INC. reported Diluted EPS of $2.26 per share (loss) for fiscal year 2025.
CAPRICOR THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.26 | -96.5% |
| 2024 | -$1.15 | -38.6% |
| 2023 | -$0.83 | +29.7% |
| 2022 | -$1.18 | -35.6% |
| 2021 | -$0.87 | +1.1% |
| 2020 | -$0.88 | -69.2% |
| 2018 | -$0.52 | -677.8% |
| 2017 | $0.09 | +108.9% |
| 2016 | -$1.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.54 | -42.1% | +5.3% |
| June 30, 2025 | -$0.57 | -62.9% | -7.5% |
| March 31, 2025 | -$0.53 | -71.0% | -39.5% |
| September 30, 2024 | -$0.38 | -52.0% | -8.6% |
| June 30, 2024 | -$0.35 | -20.7% | -12.9% |
| March 31, 2024 | -$0.31 | +0.0% | -24.0% |
| September 30, 2023 | -$0.25 | +3.8% | +13.8% |
| June 30, 2023 | -$0.29 | +0.0% | +6.5% |
- CAPRICOR THERAPEUTICS, INC. showed a decrease of -96.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, CAPRICOR THERAPEUTICS, INC.’s diluted eps has declined by 123.8% (from $1.01 per share (loss) to $2.26 per share (loss)).
- The most recent figure is from CAPRICOR THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: